Biomea Fusion, Inc. (BMEA:NASDAQ) closed at $0.612 on November 4, 2026, down 1.91% on the day. The stock trades 72.6% below its 52-week high of $2.24 and 10.9% above its 52-week low of $0.552. Over the past year, it lost 50.5%. Biomea Fusion, Inc. is part of the Health Care sector.
In 252 trading sessions since November 4, 2025, BMEA closed higher on 126 days (50%). Its best day was April 7, 2026 (+25.83%) and its worst was October 14, 2026 (-33.81%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 3 times.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Find more stocks like BMEA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.